Jim Birchenough
Stock Analyst at Wells Fargo
(2.77)
# 2,023
Out of 5,022 analysts
32
Total ratings
50%
Success rate
32.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.68 | +196.08% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $68.29 | +2.50% | 3 | Feb 22, 2024 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $18.11 | +165.05% | 3 | Feb 9, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $6 → $7 | $0.18 | +3,786.73% | 2 | Sep 22, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.39 | +9,252.52% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $3.21 | +336.14% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $26.74 | +442.26% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $118.21 | -46.71% | 5 | Oct 29, 2020 | |
| RNA Avidity Biosciences | Initiates: Overweight | n/a | $48.96 | - | 1 | Jul 7, 2020 | |
| QURE uniQure | Downgrades: Equal-Weight | $56 | $62.02 | -9.71% | 3 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $734 | $557.73 | +31.60% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $4.29 | +4,095.80% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $8.79 | +275.43% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.68
Upside: +196.08%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $68.29
Upside: +2.50%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $18.11
Upside: +165.05%
Adaptimmune Therapeutics
Sep 22, 2021
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $0.18
Upside: +3,786.73%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.39
Upside: +9,252.52%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $3.21
Upside: +336.14%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $26.74
Upside: +442.26%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $118.21
Upside: -46.71%
Avidity Biosciences
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $48.96
Upside: -
uniQure
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $62.02
Upside: -9.71%
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $557.73
Upside: +31.60%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $4.29
Upside: +4,095.80%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $8.79
Upside: +275.43%